Cytosorbents Profit Margin 2007-2018 | CTSO
Current and historical gross margin, operating margin and net profit margin for Cytosorbents (CTSO) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Cytosorbents net profit margin as of December 31, 2018 is -76.48%.
|Cytosorbents Annual Profit Margins
|Cytosorbents Quarterly Profit Margins
||Medical Products Manufacturing
CytoSorbents Corporation is a therapeutic medical device company. It develops adsorbent polymer technology for applications in the medical field, primarily to provide blood purification for the treatment of acute and chronic health complications associated with blood toxicity. The Company's product include CytoSorb, which filters cytokines and treat potentially fatal cytokine storm and BetaSorb, which remove beta2-microglobulin from the blood of patients suffering from chronic kidney failure. CytoSorbents Corporation is headquartered in Monmouth Junction, New Jersey.